Recent medical advancements cover new drug approvals, chronic condition management, and the impact of lifestyle on cognitive health.

The FDA has approved the use of rusfertide for polycythemia vera, as phase 3 trial results demonstrated it reduced the need for phlebotomy by over 50 percent.

A clinical study revealed that three-quarters of patients with giant cell arteritis remain on glucocorticoid therapy for 48 months or longer, exceeding typical treatment goals.

Research indicates that clonal hematopoiesis in atrial fibrillation patients is associated with an increased risk of hidden brain damage and accelerated cognitive decline.

Upadacitinib has shown clinical effectiveness for patients with psoriatic arthritis who have previously failed to respond to TNF inhibitor treatments.

New findings link mechanical venous thrombosis risk factors to cryptogenic ischemic strokes in young adults, particularly those with a patent foramen ovale.

Starting antiretroviral therapy immediately after an HIV diagnosis significantly improves retention in care during the critical early months of treatment.

A new trial suggests that 30 minutes of moderate-intensity exercise before sleep can help mitigate memory loss typically caused by sleep restriction.

Personal narratives in oncology highlight the significance of identifying internal cultural and personal strengths to overcome imposter syndrome in medical practice.